Personalized Medicine – Products

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Oligonucleotide therapeutics (OTs) show great promise in the field of personalized medicine as a method of targeting undruggable proteins.

Microarray-based solution enables deeper investigations of the humoral immune response in disease biology.

ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies.

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms.

A team of scientists led by the University of Oxford have achieved a significant breakthrough in detecting modifications on protein structures.

A landmark study demonstrates that precision oncology medicines could deliver a superior return on Investment for Pharma R&D vs their one size fits all counterparts.

Eremid® Genomic Services, LLC (“Eremid”) announces a significant expansion of its in-house sequencing capabilities with the installation of PacBio’s latest HiFi sequencing platform, the Revio.

Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc. for the use of their investigational CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam) technology.